Prelude Therapeutics Incorporated PRLD
3.88
(0.11)
(2.76%)
as of 25 Sep
- Market cap
- $318.4M
- P/E
- 0.0×
Follow PRLD
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(103.99%) | (99.45%) | (95.25%) | (57.73%) | |
| (76.56%) | (62.81%) | (59.64%) | (39.76%) | ||
ROIC |
(2,115.06%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(244.73%) | (172.11%) | (163.46%) | (49.89%) | |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.32) | (0.73) | (0.53) | (0.34) | |
Free Cash Flow |
(100.28) | (56.37) | (43.76) | (33.25) | |
Capital Expenditures |
(0.12) | (0.07) | — | — | |
Piotroski F-Score |
1.00 | 3.00 | 3.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
(88.26%) | (32.76%) | (30.87%) | (11.65%) | |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 492.69% | 381.68% | 309.63% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 117.06% | 105.08% | 90.92% | |
Share Based Compensation of Revenue |
0.00% | 62.24% | 48.65% | 36.99% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.90 | 0.57 | 0.56 | 0.55 | |
Depreciation/Fixed assets |
0.12 | 0.26 | 0.18 | 0.15 | |
Capex/Depreciation |
(0.19) | (0.05) | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.25 | 0.25 | 0.23 | |
Operating CF per Share |
(1.32) | (0.73) | (0.53) | (0.34) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | (519.84%) | (375.47%) | (269.75%) |
Columns are period end dates